ASH 2021 | Developing off-the-shelf CAR T-cells to treat multiple myeloma
Noopur Raje, MD, Massachusetts General Hospital, Boston, MA, shares an update on the latest developments regarding off-the-shelf CAR T-cell therapeutics for the treatment of multiple myeloma, commenting on toxicity issues that have recently emerged. Data from the Phase I UNIVERSAL trial (NCT04093596) of an anti-BCMA allogeneic CAR-T product will be presented at the ASH 2021 annual meeting. Several other trials are ongoing. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
Transcript (edited for clarity)
So there will be data presented on one of the off-the-shelf CAR-T cells. This is the allogene product, again, targeting BCMA. Dr Mailankody from Memorial Sloan Kettering will be presenting that data. The data looks really quite good. The trials right now with this off-the-shelf BCMA targeted allogeneic CA-T cells is a little bit… has been stalled because of some toxicity issues seen with the allo-products...
So there will be data presented on one of the off-the-shelf CAR-T cells. This is the allogene product, again, targeting BCMA. Dr Mailankody from Memorial Sloan Kettering will be presenting that data. The data looks really quite good. The trials right now with this off-the-shelf BCMA targeted allogeneic CA-T cells is a little bit… has been stalled because of some toxicity issues seen with the allo-products. So we’ll have to wait and see, it was not in a myeloma patient. It was in a lymphoma patient, but none the less, it is toxicity which is seen. And I think we just have to wait for the FDA to do their full due diligence to the data. And then we’ll see whether or not we can open it. There are other things that we will be looking at such as NK cell technology. Those are still trials very early on in development, and we’ll have to see where they fit into the whole paradigm of treatment for myeloma, but there are ongoing trials as we speak.
Read more...
